creatinine. Absence of ion suppression was confirmed 
by spiking experiments. The method was shown to be 
free of carryover. A good correlation was obtained 
between the LC-MS/MS method and a Jaffe method run on 
an automated analyzer (r=0.999). 
Conclusions: We have developed a fast and simple 
method for the quantification of serum creatinine by 
isotope dilution tandem mass spectrometry (ID-MS/MS) 
and we propose that this method can be used as a 
reference method by laboratories that wish to 
validate their serum creatinine automated assay. 
 
英文關鍵詞： biochip, urinary tract infection, analytical 
characteristics, clinical assessment 
 
The dipstick analysis of nitrite depends upon the conversion of nitrate (derived from the diet) 
to nitrite by the action of Gram negative bacteria (such as E.coli, Proteus, Klebsiella, Enterobacter) 
in the urine. At the acid pH of the reagent area, nitrite in the urine reacts with D-arsanilic acid to 
form a diazonium compound which in turn couples with 1,2,3,4-tetrehydrobenzo(h)quinolin-3-ol to 
produce a pink color. False positive tests occur with substances that turn the urine red, such as 
bladder analgesic phenazopyridine or the ingestion of beets. In order to achieve an accurate positive 
test result, the urine must have been retained in the bladder at least 4 hours. Therefore, it is best to 
collect a (first) morning sample or ensure the patient has not urinated in at least 4 hours. The test is 
sensitive and specific to detect ≥105 CFU per mL of urine.  However, it is not sensitive to detect 
infections caused by Gram positive bacteria (such as entercocci or staphylococci). Therefore, 
negative results do not exclude infection and must be interpreted with caution[18]. Ascorbic acid 
concentration of 25 mg/dL or higher may cause false negative results with urine specimens 
containing low amounts of nitrite ion (≤0.06 mg/dL). Patients will benefit from the smart device 
with the use of high sensitivity and specificity sensor to detect urinary nitrite and/or micro-organism 
by integrated microelectrode, microfluidics, CCD and IC chips.  
Therefore, the specific aims of the first year of this project were (1) to develop a reference 
method for serum creatinine by stable isotope-dilution tandem mass spectrometry, verified with 
purified creatinine SRM 914a from National Institute of Standards and Technology (NIST) and 
frozen human serum (SRM 967); (2) to verify the imprecision and inaccuracy of urine nitrite/nitrate 
determination by capillary electrophoresis; and (3) to assess analytical performance of the chips 
from project 1&2- preliminary evaluation. 
 
Materials and Methods 
Standard reference materials (SRM) of purified creatinine (SRM 914a) and creatinine in frozen 
human serum(SRM967)were purchased from the NIST (National Institute of Standards and 
Technology, Gaithersburg, MD, USA). Deuterated creatinine (D3-creatinine, cat. #485446) and 
HPLC grade ammonium acetate, formic acid, and methanol were purchased from Sigma-Aldrich 
(Saint-Louis, MO, USA). 
Preparation of calibrators 
Creatinine standards were prepared gravimetrically. To prepare the 1 mg/mL primary standard, 
approximately 100 mg of SRM 914a was precisely weighed and transferred to a pre-weighed 
volumetric flask. The creatinine was then dissolved in 100 mL of HCl (0.005 mol/L), and the flask 
was weighed again. The concentration of creatinine in the primary standard was obtained by 
calculating the weight of creatinine using the certified purity of SRM 914a (99.8%) and the exact 
volume of water using a density of 0.997 g/mL (at 25 °C). The highest calibrator for the calibration 
curve was then prepared gravimetrically by diluting the primary creatinine standard with water, and 
the other calibrators were obtained by serial dilutions with water using a recently calibrated positive 
displacement pipette.  
performance was assessed based on the methods described in creatinine. Also, we compared these 
results with the routine method at the Department of Pathology in NCKUH. The routine method for 
urine nitrite was the dipstick testing. Normally no nitrite is detectable in urine. Many enteric 
gram-negative organisms give positive results when bacteria number is greater than 105/mL (16.2 
μmol/L nitrite of greater). Negative test results do not exclude infection. The urinary tract infection 
may involve organisms that do not convert nitrites, or the urine may not have been held in the 
bladder greater than 4 hours.  
 
Results and Discussion 
1. Verification of method for urinary nitrate/nitrite by capillary electrophoresis (Fig. 1,2). 
 
   Fig. 1 Typical chromatogram of nitrate and nitrite by capillary electrophoresis 
   
Calibration curve: 
    
     Fig. 2 Calibration curve of nitrate and nitrite measurement 
 
  Method imprecision and inaccuracy (recovery):  
   
 
Fig. 4 Typical chromatograms of creatinine standards, left: 0.10 mg/dL and right: 50.0 
mg/dL 
 
3. Comparison with routine methods using kinetic Jaffe assay and enzymatic assay  
Results for patient samples analyzed by the LC-IDMS/MS method were compared to the results 
obtained from an IDMS traceable kinetic Jaffe colorimetric assay on an automated analyzer 
(Hitachi 917, Roche Diagnostics) and enzymatic method on Vitros autoanalyzer. All samples 
were analyzed in duplicate (n=40) and the correlation between the methods was computed by 
linear regression analysis. 
0.00 2.00 4.00 6.00 8.00 10.00
0.00
2.00
4.00
6.00
8.00
10.00
Y = 0.9845X - 0.0057
r2 = 0.9976
LC-MS/MS, mg/dL
Ja
ffe
 ra
te_
DP
 m
eth
od
, m
g/d
L
0.00 2.00 4.00 6.00 8.00 10.00
0.00
2.00
4.00
6.00
8.00
10.00 Y = 1.028X - 0.1251
r2 = 0.9976
LC-MS/MS, mg/dL
En
zym
atic
 m
eth
od
_V
itro
s, m
g/d
L
 
Fig. 5 The comparison between (top) kinetic Jaffe reaction and the established standard method 
LC-MS/MS; (bottom) enzymatic method and the established standard method LC-MS/MS. 
[15] Stokes P, O'Connor G. Development of a liquid chromatography-mass spectrometry method 
for the high-accuracy determination of creatinine in serum. J Chromatogr B Analyt Technol 
Biomed Life Sci 2003;794:125–36. 
[16] Takahashi N, Boysen G, Li F, Li Y, Swenberg JA. Tandem mass spectrometry measurements 
of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 
2007;71:266–71. 
[17] Owen LJ, Wear JE, Keevil BG. Validation of a liquid chromatography tandem mass 
spectrometry assay for serum creatinine and comparison with enzymatic and Jaffe methods. Ann 
Clin Biochem 2006;43:118–23. 
[18] Broughton PMG, Buttolph MA, Gowenlock A, Neill DW, Skentelbery RG. Recommended 
scheme for the evaluation of instruments for automatic analysis in the clinical biochemistry 
laboratory. J Clin Pathol 1969;22:278–84. 
 
已完成之目標 
第一年本計畫已完成: 
1. 建立以質譜儀方式測定血清肌酸酐的標準參考方法 
2. 建立以毛細管電泳方式測定亞硝酸鹽的標準參考方法 
3. 完成健康人臨床血清檢體之肌酸酐比對分析 
 
 
所遭遇之困難 
子計畫一所建立之晶片測定法已完成單純緩衝液環境下之測定, 但臨床檢體分析上因成分較
為複雜, 易受干擾物影響分析結果, 所以尚需要更進一步改良, 本子計畫未來亦會持續收集
並提供更多臨床檢體, 配合子計畫一改善晶片分析效能, 減少干擾物之影響 
translational research to clinical practice的進展。今年參加展示的贊助廠商近 100家，內
容與種類非常豐富，包括最新穎的儀器設備、診斷試劑、實驗用品等，令人目不暇給，
實屬豐收之旅。另外還有八○八篇壁報論文可以與國際學者互動學習。 
 
二、與會心得 
    這次有機會與二位碩士班學生一齊參與第 21 屆國際臨床生化及檢驗醫學大會獲益
良多，其內容相當豐富，筆者依個人研究領域選擇部份聆聽，以下為筆者之心得概述。 
 
在會議開幕式，除了提及 IFCC來自世界共 85個會員國外，尚有 5個附屬會員以及
在歐洲、亞太地區、拉丁美洲地區、阿拉伯地區及非洲等地均有相關之區域組織，另外
也有 41個廠商參與本次大會。 接著便由德國之歷史文化切入，並帶出德國在近代醫學
史之成就，以及檢驗醫學之重要性。本次大會之開幕演講邀請 Prof. Detlev Ganten主講，
他是 The Joint Board of Trustees of the Max Planck Institute of Colloids and Interfaces以及
The Max Planck Institute of Molecular Plant Physiology的主任；也是國際社會福利協會的
總裁 (President of World Health Summit)。他的演講題目為: “The Evolution of Medicine to 
Evolutionary Medicine”，藉由進化論的論點以及分子生物學、基因體學等之研究方法所
知悉之機制，是醫學史上重要的進展；幫助我們從傳統對疾病的了解，進入一個更透徹
的致病機轉，並藉此指出這種 Evolutionary Darwinian Medicine對研究、診斷、治療以
及預防醫學上的發展契機。之後舉辦 Welcome party，以餐會的方式和來自其他國家的
與會人士進行交流，就如同本次大會主席所言“Congresses are about people.” 
 
在大會期間，得以接觸許多不同領域的學術演講、座談會及工作坊，還有論文海報
發表、年度回顧、臨床病例討論等活動。因為本實驗室探討的題目多與肝膽疾病相關，
因此便前往聆聽與肝臟疾病相關的診斷現況，
包 括 了 Non-alcoholic fatty liver disease 
(NAFLD)、hepatocellular carcinoma (HCC)、
occult hepatitis B infection的疾病進程，以及
了解一些肝臟疾病相關的 biomarkers，例如和
Fibrosis相關的 A2M,HA,MMPs,TIMPs，以及
在兒童肝臟移植後監測其血漿中 soluble 
CD30、CD40L的濃度。 
(圖為 Dr. V. Ratziu正在講解 NAFLD) 
    有關現行與藥物基因體學相關的一些研究，例如在精神疾病治療，有著顯著個體差
異乃是由於 CYP2C19、CYP2D6、serotonin transporter alleles這些基因有著 variations，
而這些基因和代謝藥物的酵素相關，因此會使病人進一步分為 poor metabolizers、
extensive metabolizers以及 ultra-rapid metabolizers等，而致成對藥物感受性的不同。不
過這種藥物基因體學的監測，目前多半仍停留於研究階段，臨床的應用較少。另外，義
大利的學者也報導有關使用 warfarin的劑量與基因表現型 VKORC1、CYP2C9、CYP4F2
    此外，也介紹許多新的分子診斷技術，例如 DNA melting analysis、New generation 
sequencing、High throughput qPCR、Centrifugal microfluidics platforms；另外，有關 NMR- 
spectrometry、Tandem mass spectrometry等新技術，以及質譜儀在蛋白質體學上的應用
也是本會討論的重點。來自瑞士的學者 D. F. Hochstrasser發表其利用電子轉移分離技術
用於蛋白質定序上的成果。目前蛋白質定序是利用蛋白質和氮氣碰撞產生的碎片來分析
蛋白質的組成，然而此法只能用於小分子蛋白質。電子轉移分離技術是給予蛋白質多餘
電子使蛋白質骨架斷裂，不但可用於大分子蛋白質，也可用於蛋白質轉錄後修飾的成分
及位點分析。而這技術將可大大促進之後在生物標記及致病機轉上的研究。 
 
除了參加會議之外，我們也利用在柏林的期間，在 Johnson & Johnson專員Mr. Eugen 
Kretschmer 的安排下，前往距離柏林一百多公里的 Karl-Thiem Klinikum 醫院檢驗室
Institut fuer Laboratoriumsmedizin參觀。由實驗室主持人 Professor Frank Buehling親自帶
領我們參訪。首先參觀獨立於醫院外的特殊檢驗室，主要是毒物方面的檢驗項目。沿著
長廊，一間間獨立的房間分隔出不同的檢驗空間。每間房間大小不一，但每個空間似乎
都被設計過。ㄇ字型的工作檯面擺滿了不同的儀器，但檯面大小剛好與機器大小相當，
既不會浪費一絲空間，實驗人員也可以很順手的操作各項儀器設備，是相當人性化的設
計。雖然實驗室中儀器很多，但給人的感覺是井然有序的，就算當天沒有實驗的實驗室
桌面也保持的相當乾淨，可以看出平時操作是十分有條理的。之後我們繼續前往醫院內
的常規檢驗室參觀。檢驗室內的大多以自動化儀器輔助人力檢測。從檢體收受後，有機
器讀取表單，記錄不同檢體檢樣項目。之後檢體直接放入自動化軌道系統，經由兩台
Vitros儀器進行生化項目的檢測。若檢體同時需要血液等其他項檢測，系統會自動分裝
到小試管中，分門別類送到特定的區域。相關實驗人員只需定時取走檢體做檢測，不需
讓病人多抽一管血，或讓檢驗人員在整排檢體中看名單挑要處理檢體，是十分方便的設
計。除了檢測儀器設計令人敬佩，實驗室在安全措施上也很人性化。一進實驗室可見鮮
紅色的急救箱掛於牆上。緊急淋浴裝置設於實驗室中心，一旁的記錄表顯示每個月都有
人做測試，可看出他們對於實驗室安
全相當重視。這趟檢驗室參觀，讓我
們對德國人在實驗室設計和管理的
巧思有很深刻的印象。原來很多繁瑣
的細節是可以被預先考慮和規畫，並
做出令人驚艷處置的。 
 
(右後為 Eugen Kretschmer先生，左後
為 Dr. Frank Buehling) 
IFCC-Worldlab berlIn 2011
21st International Congress of Clinical Chemistry and Laboratory Medicine 
19th IFCC-EFCC European Congress of Clinical Chemistry and Laboratory Medicine
8th Annual Meeting of the German Society of Clinical Chemistry and Laboratory Medicine 
berlin, Germany, 15-19 May 2011
ICC berlin, International Congress Center
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
European Federation of Clinical Chemistry and Laboratory Medicine (EFCC)
German Society of Clinical Chemistry and Laboratory Medicine (DGKL)
Last Modified: Thu 21 Apr 2011
ABSTRACTS CD ROM 
All abstracts will be published in the Journal Clinical Chemistry and Laboratory 
Medicine (CCLM) – CD Rom version - and the abstracts will be included in the Index 
Services such as the regular CCLM issues (CAS, BIOBASE, EMBASE, MEDLINE).
WE ADVISE YOU TO PRINT THIS PAGE BECAUSE NO OTHER COMMUNICATIONS 
WILL BE SENT ON THIS SUBJECT.
For any further information you may need, please do not hesitate to contact the 
Organising Secretariat Marina Festinese, fax +39 02 6686699 
marina.festinese@mzcongressi.com
 
頁 2 / 2::IFCC-WorldLab Berlin 2011 Web Site::
2011/4/22http://www.berlin2011.org/abs/res.php
Liver and gastrointestinal diseases
Poster Abstracts – IFCC – WorldLab – EuroMedLab Berlin 2011 – Berlin, 15-19 May 2011 • DOI 10.1515/CCLM.2011.518 • S595
Clin Chem Lab Med 2011; 49, Special Suppl, pp S1 – S874, May 2011 • Copyright © by Walter de Gruyter • Berlin • New York
0793
FUNCTIONAL CAPACITY OF ALBUMIN IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
W.L. Tsai1, C.Y. Chen2, Y.J. Chen3, C.Y. Lin3, S.C. Shiesh3
1Department of Pathology, 2Internal Medicine, National Cheng Kung University Hospital, 3Department of Medical Laboratory Sci-
ence and Biotechnology, National Cheng Kung University, Tainan, Taiwan 70101
E-mail: weilunt@gmail.com
Background. Ischemia modified albumin (IMA), a marker of myocardial ischemia, was reported recently as a simple albumin func-
tion test.This study aimed to compare functional capacity of albumin in albumin solutions and to investigate the effect of albumin 
infusion on IMA in patients with cirrhosis.
Methods. IMA was measured by albumin cobalt binding test on a Beckman Spectrophotometer.IMA stability was examined in 
pooled serum stored at 4℃, -20℃ and -70℃ for 28 days. IMA in commercial human albumin solutions,AlbuRx and TBSF (CSL, 
Behring) and frozen plasma were determined.The total antioxidant capacity was determined on a Luminometer. Blood samples 
from normal subjects (N=50), patients with liver dysfunction (N=17) anddecompensated cirrhosis (N=9) were analyzed. Albumin 
and uric acid levels were determined on a Roche DP Modular analyzer.
Results. The inter- and intra-assay imprecision was less than 7% for the IMA.IMA was stable in pooled serum at all storage con-
ditions.Citrate level at 0.038 % or more lowered the IMA Results. However, uric acid up to 10.8 mg/dLdid not interfere the assay. 
IMA level was higher in frozen plasma, compared to albumin solutions. IMAR was markedly elevated in patients with cirrhosis 
(0.22±0.072), and liver dysfunction (0.20±0.107), compared to normal subjects (0.10±0.014).The supplement of albumin solutions 
in cirrhotic patients had significant effects on serum albumin (p<0.01) and IMAR (p<0.05). 
Conclusions. In this study, an IMA assay to measure albumin function was established.These data indicate that treatment with 
albumin solutions would improve the functional capacity of albumin in cirrhosis patients.
0794
VARIABILITY OF BILIRUBIN VALUES IN SAMPLES SERUM WITH HIGH TRIGLYCERIDES; INTERFERENCE OR 
CONGENITAL LIVER SYNDROMES
AURELIAN UDRISTIOIU
E-mail: aurelianu2007@yahoo.com
Background. A recurring theme in work of laboratory medicine, the interference in laboratorytesting as falsely or normal results, 
can occurs leading to delays disease recognition. The aim of this work was to identify and to interpret the variability of bilirubin 
values in serum samples together or isolated with high values of Triglycerides and variable values of Cholesterol, excluding con-
genital liver syndromes from interference, to patients presented in private laboratory for a routine pre-clinical control.
Methods. In our prospective study, in time of 30 days, we have analyzed 160 patients, performing 10 major tests; 5 substrates/
chemistries: cholesterol, total bilirubin, direct bilirubin, indirect bilirubin, triglycerides and 5 enzymatic tests, AST, ALT, ALP, LDH 
and GGT, measured on automatic analyzer Hitachi 907, hepatic viral markers (Ag HBS, Anti HCV), Elisa method, and electro-
phoresis proteins working on automatic method. Additional samples of hemogram with differential count and reticulocytes, were 
accomplished on Coulter analyzer with 22 hematological parameters. From the total patients 70 were females (20-30 years, mean 
age= 26, SD=2.6) and 90 males (25-36 year, mean age 30, SD=2.8).
Results. Laboratory studiesrevealed the following:
• the health young patients with all normal analysis were registered in 90 % percent (n=.144).
• an isolated increased Total bilirubin(1.1-7.7 mg/dl, mean=1.99 mg/dl) and an increase of Indirect bilirubin (1-4.9 mg/dl, mean 
=1.45 mg/dl, biologic reference=0.0-1.1 mg/dl, SD=0.10;CV=0.18, p=0.012, results correlated with normal liver enzymes, but 
with high Triglycerides(cut off dilution = 243 mg/dl, in samples without macroscopic aspect of turbidity), to patients from cohort 
studywere registered in 6.8%. After performing tests of Indirect bilirubin in dilution 1/5, only 2.8% of tests were with normal val-
ues (negative predictive value=66%) and 4% of tests have had the same high results, meaning the congenital liver syndromes 
(positive predictive value=72%).
Conclusions. Elevated values of triglycerides, correlated with increased levels of total bilirubin in these cases, can present a 
differential diagnosis with liver congenital syndromes with isolated high indirect bilirubin values (Gilbert syndrome or Crigler-Najjar 
syndrome).
國科會補助計畫衍生研發成果推廣資料表
日期:2012/07/10
國科會補助計畫
計畫名稱: 子計畫三：腎功能與尿道感染之微晶片的分析特性與臨床評估(1/3)
計畫主持人: 謝淑珠
計畫編號: 100-2220-E-006-019- 學門領域: 智慧電子科技計畫-整合型學術研
究計畫
無研發成果推廣資料
其他成果 
(無法以量化表達之成
果如辦理學術活動、獲
得獎項、重要國際合
作、研究成果國際影響
力及其他協助產業技
術發展之具體效益事
項等，請以文字敘述填
列。) 
無 
 成果項目 量化 名稱或內容性質簡述 
測驗工具(含質性與量性) 0  
課程/模組 0  
電腦及網路系統或工具 0  
教材 0  
舉辦之活動/競賽 0  
研討會/工作坊 0  
電子報、網站 0  
科 
教 
處 
計 
畫 
加 
填 
項 
目 計畫成果推廣之參與（閱聽）人數 0  
 
